Mentice (MNTC) investor relations material

Executive summary

• Achieved strong revenue growth in Q2 2026, with net sales of 80 MSEK (28% organic growth), marking the fourth consecutive quarter of net sales and EBITDA growth.

• Order intake reached 79 MSEK, up 41% organically year-over-year, mainly from the Americas.

• EBITDA improved to 6.3 MSEK in Q2, compared to -8.1 MSEK last year, with net income at -0.9 MSEK, a significant improvement from -17.6 MSEK.

• Cash position improved to 61 MSEK at quarter-end, supporting future R&D investments.

• Announced a strategic partnership with Siemens Healthineers to integrate Ankyras solutions into ARTIS icono systems.

Financial highlights

• Net sales for Q2 were 80 MSEK, up 26% year-over-year (28% organic growth).

• EBITDA margin improved to 8% in Q2, up from -1% in Q2 2025.

• Operating cash flow was 8.3 MSEK, compared to -7.3 MSEK in Q2 last year.

• Order book stands at 128 MSEK, with 79 MSEK expected to convert to sales in H2 2026.

• Rolling 12-month sales reached 303 MSEK, up from 262 MSEK a year ago.

Outlook and guidance

• Management expresses confidence in continued growth, supported by a strong order book and lean cost structure.

• Focus remains on executing and delivering ongoing project development orders, with capacity increases planned for the MDI segment.

• Gross margin is expected to remain at current levels, with FX and outsourcing impacting margin dynamics.

• Medium- to long-term strategy for the Healthcare Systems segment is under development.

• Healthcare Systems segment expected to recover, with deals delayed to later quarters.